RxDoctor Payments Data

Fabio Nascimento E Silva, MD

Epilepsy · Saint Louis, MONPI 1881045573

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,723 of the $11,221 with a category attached, or 68.8%. UCB, Inc. accounts for 86.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $5,462 and has fallen 97.7% since, to $128 in 2025.

$11,221in general payments, 2019–2025

Across 23 payments — averaging $487.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$10K
  • DIXI Medical USA Corp$729
  • Biocodex, Inc.$398
  • Cadwell Industries, Inc$150
  • SK Life Science, Inc.$120
  • Neurelis, Inc.$83
  • plus $35 from 1 others

What the payments were for

  • Consulting fees$7,72369%
  • Travel & lodging$1,76216%
  • Food & beverage$1,73615%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.17$9,705
DIXI Medical USA Corp1$729
Biocodex, Inc.1$398
Cadwell Industries, Inc1$150
SK Life Science, Inc.1$120
Neurelis, Inc.1$83
Livanova USA, Inc.1$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,221 in reported general payments places this provider in the 80th percentile of 26 epilepsy providers in Missouri.

See all epilepsy providers in Missouri

Medicare billing

Part B allowed, 2024
$31,719
Medicare patients
140
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)20$156,571
XcopriCenobamate48$90,925
Rufinamide20$36,159
Clobazam71$15,013
Lacosamide34$5,872
Levetiracetam135$5,475
Lamotrigine ErLamotrigine20$4,010
Carbamazepine ErCarbamazepine15$3,294
Divalproex Sodium12$2,569
Levetiracetam ErLevetiracetam16$2,569
Divalproex Sodium ErDivalproex Sodium24$1,254
Zonisamide38$974
Carbamazepine18$792
Lamotrigine45$428
Clonazepam12$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$120$90,92548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 epilepsy providers in Missouri.

Other epilepsy in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →